Consistent with above findings, an unfavorable prognosis in AML patients with high mRNA levels of TBCB was exhibited in the independent external validation cohort, GSE37642 (AML, n = 134; p = 0.007; Figure 2B). The gene discussed is TBCB; the disease is acute myeloid leukemia.